Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Completed · Phase 1/Phase 2
Conditions studied: Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when given with oxaliplatin and fluorouracil and to see how well they work in treating patients with metastatic or unresectable stomach cancer, gastroesophageal junction cancer, or other solid tumor.
Key facts
- Study ID
- NCT00711243
- Run by
- Northwestern University
- People needed
- 59
- Starts
- 2005-04-20
- Expected to finish
- 2011-02-25
- Last updated by the study team
- 2019-02-26
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.